Similar articles

• Intranasal Naloxone Administration.

  Skulberg AK, Tylleskar I, Dale O. Skulberg AK, et al. N Engl J Med. 2021 Jun 17;384(24):e96. doi: 10.1056/NEJMc2106983. N Engl J Med. 2021. PMID: 34133872 No abstract available.
• Severe prolonged agitation due to intranasal naloxone overexposure.

  Brenner DS, Stolbach AI, Zschoche J, Bright L. Brenner DS, et al. Am J Emerg Med. 2021 Apr;42:261.e1-261.e2. doi: 10.1016/j.ajem.2020.08.069. Epub 2020 Aug 28. Am J Emerg Med. 2021. PMID: 32919810 No abstract available.
• President's message: Food and Drug Administration approved naloxone and continued use of improvised nasal naloxone: What is a treatment advocate and educator to do?

  Morrone WR. Morrone WR. J Addict Dis. 2016 Oct-Dec;35(4):339-345. doi: 10.1080/10550887.2016.1226582. J Addict Dis. 2016. PMID: 27731792 No abstract available.
• Intranasal naloxone for the treatment of suspected heroin overdose.

  Kerr D, Dietze P, Kelly AM. Kerr D, et al. Addiction. 2008 Mar;103(3):379-86. doi: 10.1111/j.1360-0443.2007.02097.x. Addiction. 2008. PMID: 18269360 Review.
• International patent applications for non-injectable naloxone for opioid overdose reversal: Exploratory search and retrieve analysis of the PatentScope database.

  McDonald R, Danielsson Glende Ø, Dale O, Strang J. McDonald R, et al. Drug Alcohol Rev. 2018 Feb;37(2):205-215. doi: 10.1111/dar.12571. Epub 2017 Jun 8. Drug Alcohol Rev. 2018. PMID: 28597483 Review.